Concord Biotech Limited vs Max Healthcare Institute Limited
Last updated: 23 October 2026
Welcome to MoneyDock's latest comparison, pitting two significant players in the Indian healthcare and pharmaceutical sectors against each other: Concord Biotech Limited (CONCORDBIO.NS) and Max Healthcare Institute Limited (MAXHEALTH.NS). While Concord Biotech operates primarily in the biopharmaceutical space, focusing on fermentation-based APIs (Active Pharmaceutical Ingredients) and formulations, Max Healthcare is a prominent healthcare provider with a network of hospitals across India, offering a wide range of medical services. Both companies are crucial to India's health infrastructure, albeit in different capacities, making a comparative analysis valuable for investors looking at the broader healthcare investment landscape. This analysis will delve into their recent market performance, stability, and potential investment appeal based on available financial data.
Key Financial Metrics Comparison
| Metric | Concord Biotech Limited | Max Healthcare Institute Limited |
|---|---|---|
| Current Price | ₹1229.30 | ₹815.00 |
| 52W High | ₹1579.40 | ₹1153.40 |
| 52W Low | ₹1014.80 | ₹815.00 |
| 1-Year Return | -7.65% | -20.96% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
When we look at valuation, both companies currently have 'N/A' for their Trailing P/E and Market Cap, which limits a direct valuation comparison based on these common metrics. However, we can infer some aspects from their current prices relative to their 52-week ranges. Concord Biotech is trading at ₹1229.30, which is closer to its 52W Low of ₹1014.80 than its 52W High of ₹1579.40. Max Healthcare, on the other hand, is trading precisely at its 52W Low of ₹815.00, significantly below its 52W High of ₹1153.40. This suggests that Max Healthcare might be experiencing more downward pressure or a deeper correction compared to Concord Biotech.
In terms of returns, both companies have delivered negative 1-year returns, indicating a challenging period for both sectors. Concord Biotech recorded a -7.65% 1-year return, while Max Healthcare saw a more substantial decline of -20.96%. From a returns perspective, Concord Biotech has clearly outperformed Max Healthcare over the past year, experiencing a less severe downturn. This makes Concord Biotech the winner in the returns category, albeit still being in negative territory.
Regarding stability, we can examine their price proximity to their 52-week lows. Max Healthcare is currently trading at its 52W Low, suggesting potential instability or a strong bearish sentiment at present. Concord Biotech, while also down from its high, is still above its 52W Low, indicating slightly more resilience within its 52-week range. However, without P/E ratios or market capitalization figures, a comprehensive assessment of financial stability is challenging. Based purely on recent price action relative to their annual ranges, Concord Biotech appears to exhibit relatively better short-term price stability.
MoneyDock Verdict
For Aggressive Investors: Given the deeper correction and trading at its 52W Low, Max Healthcare might present a higher-risk, potentially higher-reward opportunity if one believes in a strong rebound. However, the lack of P/E makes it a speculative bet. Concord Biotech, with its less severe decline, might be considered less aggressive, but still carries risk.
For Conservative Investors: Both stocks show negative 1-year returns and lack key valuation metrics (P/E, Market Cap). Conservative investors might prefer to wait for more comprehensive financial data and a more stable market trend before considering an investment in either company.
For Long-Term SIP Investors: For long-term SIP investors, Concord Biotech's comparatively better 1-year return (-7.65% vs -20.96%) suggests it has weathered the recent market headwinds slightly better. While both are in a downturn, Concord Biotech's performance indicates potentially stronger underlying business resilience. However, without valuation metrics like P/E and Market Cap, it's difficult to ascertain if current prices represent a good long-term entry point based on fundamental value. Investors should conduct further due diligence.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.